Patents by Inventor Gurmit S. Gill
Gurmit S. Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180228778Abstract: Compositions comprising S1P receptor modulators and at least one compound selected from one or more of the group consisting of steroids, opioids and non-steroidal anti-inflammatory drugs are provided. The compositions find use in the treatment of disease, particularly inflammation and immune mediated disorders.Type: ApplicationFiled: August 11, 2016Publication date: August 16, 2018Inventors: Gurmit S. Gill, Damian W. Grobelny
-
Patent number: 9707205Abstract: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.Type: GrantFiled: October 22, 2015Date of Patent: July 18, 2017Assignee: AKAAL PHARMA PTY LTD.Inventors: Gurmit S. Gill, Damian W. Grobelny
-
Publication number: 20160038455Abstract: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.Type: ApplicationFiled: October 22, 2015Publication date: February 11, 2016Applicant: AKAAL PHARMA PTY LTD.Inventors: GURMIT S. GILL, DAMIAN W. GROBELNY
-
Patent number: 9193716Abstract: The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.Type: GrantFiled: October 29, 2013Date of Patent: November 24, 2015Assignee: Akaal Pharma PTY LTD.Inventors: Gurmit S. Gill, Damian W. Grobelny
-
Patent number: 9181182Abstract: The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.Type: GrantFiled: October 16, 2009Date of Patent: November 10, 2015Assignee: Akaal Pharma PTY LTDInventors: Damian W. Grobelny, Gurmit S. Gill
-
Publication number: 20140066427Abstract: The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.Type: ApplicationFiled: October 29, 2013Publication date: March 6, 2014Applicant: AKAAL PHARMA PTY LTD.Inventors: Gurmit S. Gill, Damian W. Grobelny
-
Patent number: 8592399Abstract: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.Type: GrantFiled: October 19, 2009Date of Patent: November 26, 2013Assignee: Akaal Pharma Pty Ltd.Inventors: Gurmit S. Gill, Damian W. Grobelny
-
Publication number: 20120034270Abstract: The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.Type: ApplicationFiled: October 16, 2009Publication date: February 9, 2012Applicant: Akaal Pharma Pty LtdInventors: Damian W. Grobelny, Gurmit S. Gill
-
Publication number: 20110318388Abstract: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.Type: ApplicationFiled: October 19, 2009Publication date: December 29, 2011Applicant: Akaal Pharma Pty LtdInventors: Gurmit S. Gill, Damian W. Grobelny